上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
KIRA6 纯度: 99.86%
KIRA6,小分子 IRE1α RNase 激酶抑制剂,IC50 值为0.6 µM。 KIRA6 可以触发细胞凋亡 (apoptotic) 反应。
KIRA6 Chemical Structure
CAS No. : 1589527-65-0
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
5 mg | ¥1500 | In-stock | |
10 mg | ¥2400 | In-stock | |
25 mg | ¥4900 | 询价 | |
50 mg | ¥7800 | 询价 | |
100 mg | 询价 | ||
200 mg | 询价 |
* Please select Quantity before adding items.
KIRA6 相关产品
•相关化合物库:
- Covalent Screening Library Plus
- Bioactive Compound Library Plus
- Cell Cycle/DNA Damage Compound Library
- Immunology/Inflammation Compound Library
- Kinase Inhibitor Library
- Anti-Cancer Compound Library
- Anti-Aging Compound Library
- Covalent Screening Library
- Diabetes Related Compound Library
- Endoplasmic Reticulum Stress Compound Library
生物活性 |
KIRA6 is an advanced small-molecule IRE1α RNase kinase inhibitor with an IC50 of 0.6 µM[2]. KIRA6 can trigger an apoptotic response[1]. |
IC50 & Target |
IC50: 0.6 µM (IRE1α RNase kinase)[2] |
||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
KIRA6 (1nM-100μM) bounds to the cytoplasmic domain of KIT with a Kd value of 10.8 µM[1]. KIRA6 (10-1000 nM; 72 hours) strongly compromises the viability of the KIT-dependent cell line HMC-1.1 at the low nM concentration, in a manner that coincided with KIT blockade[1]. KIRA6 (10-1000 nM; 1 hour) reduces signaling output of KIT, including the phosphorylation of KIT as well as its downstream signaling modules, PSTAT5 and phosphorylated ERK1/2[1]. KIRA6 (1 μM; 0-48 hours) inhibits Ins1 mRNA decay from IRE1α hyperactivation at a dose-dependent manner[2]. KIRA6 (0.1-10μM; 72 hours) dose-dependently reduces 1NM-PP1 potentiation of Ins1 apoptosis during ER stress in a dose-dependent manner[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay[1]
Western Blot Analysis[1]
RT-PCR[2]
Apoptosis Analysis[2]
|
||||||||||||||||||||||||||||||||
体内研究 (In Vivo) |
KIRA6 (intraperitoneal injection; 5 mg/kg; 37 days) shows significant amelioration of random glucose levels over several weeks compared to vehicle, both fed ad lib[2]. KIRA6 (intraperitoneal injection; 5 mg/kg; 21 or 18 days postinjections) increases both plasma insulin and C-peptide levels, remains insulin-positive islet areas at high level after stopping injections in the Akita Mouse[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||||||||||||||||||
分子量 |
518.53 |
||||||||||||||||||||||||||||||||
Formula |
C28H25F3N6O |
||||||||||||||||||||||||||||||||
CAS 号 |
1589527-65-0 |
||||||||||||||||||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||||||||||||||||||
储存方式 |
|
||||||||||||||||||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 6.25 mg/mL (12.05 mM; Need ultrasonic) Ethanol : 2 mg/mL (3.86 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务